Dragonfly Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2038
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 17, 2027The maintenance fee for Heterodimeric Fc-fused proteins (US 11,787,864) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Multi-Specific Binding Proteins That Bind NKG2D, CD16, and a Tumor-Associated Antigen for Activation of Natural Killer Cells and Therapeutic Uses Thereof to Treat Cancer (US 11,834,506) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 2 fees due Jul 30, 2027
- 1 fee due Sep 26, 2027The maintenance fee for Antibody Variable Domains Targeting the NKG2D Receptor (US 11,939,384) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,760,105 | Multi-Specific Binding Proteins Binding Bcma, NKG2D and CD16 and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,780,925 | Proteins Binding NKG2D, CD16 and a Tumor-Associated Antigen In force · High confidence | In force | High confidence | |
| US 11,834,506 | Multi-Specific Binding Proteins That Bind NKG2D, CD16, and a Tumor-Associated Antigen for Activation of Natural Killer Cells and Therapeutic Uses Thereof to Treat Cancer In force · High confidence | In force | High confidence | |
| US 11,884,732 | Proteins Binding HER2, NKG2D and CD16 In force · High confidence | In force | High confidence | |
| US 11,939,384 | Antibody Variable Domains Targeting the NKG2D Receptor In force · High confidence | In force | High confidence | |
| US 12,129,300 | Antibody Variable Domains Targeting the NKG2D Receptor In force · High confidence | In force | High confidence | |
| US 12,264,200 | Antibody Variable Domains Targeting the NKG2D Receptor In force · High confidence | In force | High confidence | |
| US 12,378,318 | Proteins Binding NKG2D, CD16 and a Tumor-Associated Antigen In force · High confidence | In force | High confidence | |
| US 12,384,851 | Multi-Specific Binding Proteins That Bind Bcma, NKG2D and CD16, and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,787,864 | Heterodimeric Fc-fused proteins In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 13 abandoned · 32 no status recorded